Bitter fights over price threaten to keep gene therapies out of Europe; Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

Taking stock of the drug industry, from the lab to the medicine chest

October 4, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Eros Dervishi for STAT STAT+ | Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again Life-changing treatments are colliding with cost-conscious national health systems empowered to negotiate prices. By Andrew Joseph STAT+ | Colombia set to issue a compulsory license for an HIV medicine sold by GSK's ViiV The move underscores ongoing friction between the pharmaceutical industry and cash-strapped governments around the world. By Ed Silverman STAT+ | FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases The episode was traced to a Fresenius Kabi manufacturing facility in Puerto Rico that previously received an FDA warning. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser